Plain-English translation of NCT07045909 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 2 — Testing in a bigger group (up to a few hundred people) to see if the treatment actually works and is still safe.
This trial is testing a new treatment called for people with newly diagnosed multiple myeloma. The medication is made from your own immune cells, which are collected, modified in a laboratory to fight cancer, and then given back to you as a single infusion. This approach aims to help your body's immune system recognize and destroy myeloma cells more effectively.
Multiple myeloma is a serious blood cancer, and while current treatments help many patients, doctors are seeking new options to improve outcomes and offer alternatives for patients of different ages and health situations. This medication represents a newer approach using the body's own immune cells to fight the disease.
You likely qualify if…
You likely don't qualify if…
You would first receive standard chemotherapy induction treatment (either 6 cycles or 4 cycles depending on your group), during which your immune cells are collected through a procedure called leukapheresis. After induction, you receive a short course of lymphodepleting chemotherapy to prepare your body, followed by a single infusion of the modified cells. You would then be monitored closely for side effects and treatment response, with some participants receiving additional maintenance medication for up to 2 years. The entire process typically takes several months from start to finish, with regular hospital visits and blood tests throughout.
AI-generated summary from trial data · Jun 4, 2026 · Not medical advice
Spain